DMT Treatment Review
April 26, 2021
April 26, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by The Consortium for Multiple Sclerosis Centers in collaboration with The France Foundation.
This activity is supported by an independent education grant from Biogen and Sanofi Genzyme.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Nursing Contact Hours (1.0 in the area of pharmacology)
- Pharmacists - This knowledge-based activity (UAN JA4008165-9999-21-004-H01-P) qualifies for 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit. Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the activity. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.
All other health care professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of neurologists, nursing professionals, pharmacists, and other members of the health care team who manage patients with MS.
A widening field of MS treatment options presents clinicians with an increasingly complex decision-making process. Listen as MS expert, Dr. Patricia Coyle, reviews the latest in MS disease modifying therapies.
Upon completion of this activity, participants should be better able to:
- Recognize the significance of MS phenotypes, and characteristic features, with an emphasis on progressive disease
- Apply a more targeted approach to the treatment of MS when selecting therapy
Patricia K. Coyle, MD
Director, MS Comprehensive Care Center
Professor of Neurology
Stony Brook University Neurosciences Institute
Stony Brook, NY
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation
The CMSC designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit Designation
The CMSC designates this enduring material for 1.0 contact hours of continuing education (1.0 in the area of pharmacology).
Pharmacists Credit Designation
This knowledge-based activity (UAN JA4008165-9999-21-004-H01-P) qualifies for 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit. Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the activity. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.
Non-Physician Credit Designation
Certificate of Completion: A Certificate of Completion may be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.
Disclosures of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, the Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and TFF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and TFF are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Patricia K. Coyle, MD
- Consultant: Accordant, Alexion, Bayer, Biogen, Genentech/Roche, GlaxoSmithKline, Mylan, Novartis, Sanofi Genzyme, Serono, and TG Therapeutics
- Contract Researcher: Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, and Novartis
Activity Staff Disclosures
The planners, reviewers, editors, staff, continuing education committee, and other members at CMSC who control content have no relevant financial relationships to disclose.
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation (TFF) require CME/CE faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. CMSC and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
The Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation (TFF) present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, Consortium of Multiple Sclerosis Centers, and the commercial supporter(s) assume no liability for the information herein.
For CME questions please contact: firstname.lastname@example.org